Monsanto Technology LLC

Confluence Life Sciences, Inc.

Pharmacia Corporation

G.d. Searle & Company

Novozymes Bioag A/s

Pfizer Corporation

Aclaris Life Sciences, Inc.

Shaun Raj Selness

Balekudru Devadas

Rajesh Devraj

Joseph B Monahan

John Jeffrey Talley

Gunnar J Hanson

Michael L Vazquez

Daniel L Flynn

Michael John Clare

Richard M Weier

Richard A Partis

Matthew James Graneto

Paul Waddell Collins

Ish K Khanna

Suzanne S Metz

Francis J Koszyk

Michael A Stealey

Michael S South

Susan Landis Hockerman

He Huang

Susan J Hartmann

Shashidhar N Rao

Cathleen Elizabeth Hanau

Yi Yu

Lifeng Geng

Shuyuan Liao

Joyce Zuowu Crich

Win Naing

Thao D Perry

John Walker

Xiangdong Xu

John F Schindler

Li Huang Xing

Dave Greenshields

Ashok S Naraian

Michael Hepperle

Hui Han

Urszula Slomczynska

Yiwei Ding

Michael E Hepperle

Ashok Anantanarayan

Syaulan Yang

Shuang Liu

Richard C Durley

Margaret Lanahan Grapperhaus

Brian S Hickory

Ian L Scott

Michele A Promo

Eddine Saiah

Mark E Schnute

Terri L Boehm

Robert Owen Hughes

Christoph Wolfgang Zapf

Daniel Patrick Walker

Paul Vincent Rucker

Zhao-Kui Wan

Dennis K Anderson

Kristi Woods

Seungil Han

John Robert Springer

Thomas Dale Owen

Kevin D Jerome

Michael Mao

Daniel James Seyer

Aruna Sambandam

Jerry D Clark

Lisa L McDermott

Patrick H Lau

Jodi L Moe

Partha Mudipalli

Christine B Seymour

Edgardo Alvira

Michelle Ann Schmidt

Huey S Shieh

John E Baldus

Vincent Martin

Shekhar Viswanath

Ronald Francis Colletti

Danny James Garland

Heather M Madsen

Xiangdong Xi

Radhika M Blevis-Bal

Laura D Marruto

Jeff Hitchcock

Kevin F McGee

William Abraham

Jon P Lawson

Sastry A Kunda

Gopichand Yalamanchili

Kimberley C Allen

Gopi Yalamanchili

Tobin C Schilke

Todd Boehlow

Dan R Dukesherer

Albert D Edney

Tom Fevig

Kimberly K Allen

Albert D Edeny

Daniel R Dukesherer

Gulam Ahmed

Provided herein are containerized liquid formulations comprising a plurality of agrochemicals. The formulations comprise a plurality of parallel liquid layers, wherein each layer is disposed within the container such that it is in contact with at least one adjacent layer at an interface. Also provided are methods of preparing, storing, shipping, and using the containerized liquid formulations.

Containerized liquid formulations

Provided herein are treated seeds and methods for the preparation of treated seeds comprising a biological agent and a polymeric coating.

Processes for the preparation of treated seeds

[A]queous inoculant compositions comprising microbial spores and methods for enhancing the survival and/or stability of microbial spores in an inoculant composition. In some embodiments, the aqueous inoculant compositions comprise microbial spores, one or more dispersants, one or more protectants, one or more aqueous additives in a non-aqueous liquid carrier.

Stable inoculant compositions and methods for producing same

The present disclosure provides aqueous inoculant compositions and methods for enhancing the survival and/or stability of microbial spores in an inoculant composition. In some embodiments, aqueous inoculant compositions of the present disclosure comprise microbial spores, one or more dispersants, one or more protectants, one or more aqueous additives and a non-aqueous liquid carrier.

The present disclosure provides non-aqueous inoculant compositions and methods for enhancing the survival and/or stability of microbial spores in an inoculant composition. In some embodiments, inoculant compositions of the present disclosure comprise microbial spores, one or more dispersants, one or more protectants and a non-aqueous liquid carrier.

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I) 

Bruton's tyrosine kinase inhibitors

Provided herein are aqueous suspension concentrate compositions comprising biologically active 3,5-disubstituted-1,2,4-oxadiazoles or salts thereof that are useful, for example, in the control of nematodes.

Nematicidal aqueous suspension concentrate compositions

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. 

Provided herein are aqueous suspension concentrate compositions comprising biologically active 3,5-disubstituted-1,2,4-oxadiazoles or salts thereof that are useful, for example, in the control of nematodes. Nematodes are active, flexible, elongate organisms that live on moist surfaces or in liquid environments, including films of water within soil and moist tissues within other organisms. Many species of nematodes have evolved to be very successful parasites of plants and animals and, as a result, are responsible for significant economic losses in agriculture and livestock.

The present disclosure provides methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis, having the structure of Formula (I): wherein R, R, R, R, Rand X are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds

The present disclosure provides pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, having the structure of Formula (I): wherein R, R, R, R, R, X and Y are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

Substituted pyridinone-pyridinyl compounds

Growing community of inventors

Chesterfield, MO, United States of America

Shaun Raj Selness